Study: Expanded CER Process Will Reduce Investment in Medical Technologies by $10 B | Healthcare Informatics Magazine | Health IT | Information Technology Skip to content Skip to navigation

Study: Expanded CER Process Will Reduce Investment in Medical Technologies by $10 B

July 14, 2011
by root
| Reprints

A new research study released by the Pacific Research Institute (PRI), a San Francisco-based free-market think tank, examines an expanded quasi-federal comparative effectiveness review (CER) process and the negative effects on private-sector investment in research and development of new and improved medical technologies. Under conservative assumptions, R&D investment in pharmaceuticals, medical devices and equipment would be reduced by about $10 billion per year over the period from 2014 through 2025. "Medicare Auctions for Durable Medical Equipment" was authored by PRI senior policy fellow Benjamin Zycher, Ph.D.

Comparative Effectiveness Review (CER) is defined by the Congressional Budget Office as "a rigorous evaluation of the impact of different options that are available for treating a given medical condition for a particular set of patients." Because policymakers have powerful incentives to restrain the growth of health care expenditures, an expanded federal role in CER, whether direct or indirect, will induce responses from the private sector as a result of expectations of how CER findings will be used by policymakers. For firms investing in and developing medical technologies, these expectations include an increased need for private clinical testing, increased pricing pressures, increased risk of non-approval or limited approval for federally-financed programs, a shortening of the patent period and delays in expected sales revenues.

Using data from the National Science Foundation and other sources, the report concludes that under conservative assumptions, R&D investment in new and improved pharmaceuticals and medical devices and equipment would be reduced by about 10-12 percent. This reduction in the flow of new and improved technology would impose an expected loss of about 5 million life-years annually, with a conservative economic value of $500 billion - an amount substantially greater than the entire U.S. market for pharmaceuticals, devices and equipment.


Topics

News

Former Michigan Governor to Serve as Chair of DRIVE Health

Former Michigan Governor John Engler will serve as chair of the DRIVE Health Initiative, a campaign aimed at accelerating the U.S. health system's transition to value-based care.

NJ Medical Group Launches Statewide HIE, OneHealth New Jersey

The Medical Society of New Jersey (MSNJ) recently launched OneHealth New Jersey, a statewide health information exchange (HIE) that is now live.

Survey: 70% of Providers Using Off-Premises Computing for Some Applications

A survey conducted by KLAS Research found that 70 percent of healthcare organizations have moved at least some applications or IT infrastructure off-premises.

AMIA Warns of Tax Bill’s Impact on Graduate School Programs in Informatics

Provisions in the Republican tax bill that would count graduate student tuition waivers as taxable income would have detrimental impacts on the viability of fields such as informatics, according to the American Medical Informatics Association.

Appalachia Project to Study Relationship Between Increased Broadband Access, Improved Cancer Care

The Federal Communications Commission and the National Cancer Institute have joined forces to focus on how increasing broadband access and adoption in rural areas can improve the lives of rural cancer patients.

Survey: By 2019, 60% of Medicare Revenues will be Tied to Risk

Medical groups and health systems that are members of AMGA (the American Medical Group Association) expect that nearly 60 percent of their revenues from Medicare will be from risk-based products by 2019, according to the results from a recent survey.